
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release